Crizocent 250 Capsules — Crizotinib 250 mg (60 Capsules) Incepta

Crizocent is indicated for the treatment of patients based on genetic diagnostic confirmation of:

• 🔹 Metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive.
• 🔹 Metastatic non-small cell lung cancer (NSCLC) that is ROS1-positive.

Sales Unit: 1 bottle containing 60 capsules, each containing 250 mg of Crizotinib.

⚠️ APPLICATION INSTRUCTIONS:

• Dosage: The standard recommended dose is 250 mg taken orally twice daily (total daily dose 500 mg).
• Method: Swallow capsules whole. May be taken with or without food.
• Dietary Restrictions: Avoid grapefruit and grapefruit juice during treatment, as they may increase the concentration of the drug in the blood.
• Storage: Store in a cool, dry place at a temperature not exceeding 30°C.

• ⛔ Organ Impairment: Severe renal or hepatic impairment requires strict medical supervision and possible dose adjustment.
• ⛔ Pregnancy: Known to cause fetal harm; use during pregnancy or breastfeeding is strictly prohibited.
• Hypersensitivity to Crizotinib or any of its excipients.
• Congenital long QT syndrome or concurrent use of drugs that prolong the QT interval.

Supervision by a healthcare professional experienced in oncology is required. Potential side effects include:

• 👁️ Vision: Visual disturbances (blurred vision, double vision, or photopsia), typically occurring early in treatment.
• 🤢 Gastrointestinal: Nausea, diarrhea, vomiting, and constipation.
• 🩸 Hepatobiliary: Elevated liver enzymes (ALT, AST) and neutropenia.
• 🏃‍♂️ General: Edema (swelling), fatigue, and dizziness.